Get the Stockscreener App
2.52
0.80%
0.02
After Hours:
2.58
0.06
+2.38%
Perspective Therapeutics Inc stock is traded at $2.52, with a volume of 1.80M.
It is up +0.80% in the last 24 hours and down -23.40% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$2.50
Open:
$2.5
24h Volume:
1.80M
Relative Volume:
1.02
Market Cap:
$287.66M
Revenue:
$618.00K
Net Income/Loss:
$-111.65M
P/E Ratio:
-1.8052
EPS:
-1.396
Net Cash Flow:
$-107.53M
1W Performance:
-12.50%
1M Performance:
-23.40%
6M Performance:
-44.25%
1Y Performance:
-21.00%
1-Day Range:
$2.45
$2.525
1-Week Range:
$2.44
$3.03
52-Week Range:
$1.955
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
2.52 | 287.66M | 618.00K | -111.65M | -107.53M | -1.396 |
ABT
Abbott Laboratories
|
101.29 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
88.64 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
272.36 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.92 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.29 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | Piper Sandler | Overweight |
| Nov-24-25 | Resumed | Truist | Buy |
| Oct-10-25 | Initiated | BTIG Research | Buy |
| Mar-13-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-01-24 | Initiated | Wedbush | Outperform |
| Sep-25-24 | Initiated | Truist | Buy |
| Jul-25-24 | Initiated | BofA Securities | Buy |
| May-09-24 | Initiated | Cantor Fitzgerald | Overweight |
View All
Perspective Therapeutics Inc Stock (CATX) Latest News
Form 13D/A Perspective Therapeutics For: 26 September By Investing.com - Investing.com Canada
Perspective Therapeutics Inc (CATX) Stock Price Target & Forecast - tradingkey.com
After selling nearly 1.4 million shares in one day, a Perspective Therapeutics (CATX) holder still has a stake. - Stock Titan
Perspective Therapeutics Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesEPS Consistency Score - siam.in
Perspective Therapeutics (CATX) Climbs 3.13% to $2.97, Nearing Resistance at $3.12Mutual Fund Flow - dars.gov.et
Perspective Therapeutics, Inc.(NYSEAM:CATX) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
This $3 Biotech Could Be Worth $11.45, Analyst Says - benzinga.com
William Blair initiates Perspective Therapeutics stock with outperform rating - Investing.com
William Blair Initiates Perspective Therapeutics With Outperform Rating - marketscreener.com
William Blair initiates Perspective Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
William Blair Initiates Perspective Therapeutics(CATX.US) With Buy Rating - Moomoo
Perspective Therapeutics Inc (CATX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BMO Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Perspective Therapeutics partners with Merck on cancer trial By Investing.com - Investing.com South Africa
Perspective Therapeutics partners with Merck on cancer trial - Investing.com
Form 8K Perspective Therapeutics Inc For: 14 September By Investing.com - Investing.com UK
Merck joins Perspective Therapeutics (NYSE: CATX) to test Keytruda combo in Phase 1/2a cancer trial - Stock Titan
Perspective Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate PSV359 in Combination with Keytruda in Advanced FAP-α-Positive Solid Tumors - quiverquant.com
Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell - marketscreener.com
Perspective Therapeutics to present NET therapy trial data - grafa.com
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026 - Yahoo Finance
Perspective Therapeutics (CATX) Insider Sale: 10% Owner Lantheus Alpha Therapy, LLC Sells 247,932 Shares - GuruFocus
Perspective Therapeutics updates corporate presentation highlighting 212Pb pipeline, $45B addressable market - TradingView
Perspective Therapeutics (CATX) highlights 3 cancer drug programs - Stock Titan
Perspective Therapeutics (CATX) holder sells stock near $3.10 - Stock Titan
Lantheus Alpha Therapy Sells 113,914 Perspective Therapeutics (AMEX: CATX) Shares at Up to $3.14 Per Share - Kalkine Media
Lantheus Group Reduces Stake in Perspective Therapeutics (AMEX: CATX) to 10% Amid Activist 13D Filing - Kalkine Media
Lantheus Holdings (NASDAQ: LNTH) 10% Stakeholder Alpha Therapy Sells 42,129 Shares at $3.11 Each - Kalkine Media
Perspective Therapeutics (CATX) Insider Sell: 10% Owner Lantheus Alpha Therapy, LLC Disposes of 42,129 Shares - GuruFocus
Lantheus Holdings (NASDAQ: LNTH) Disposes of 35,769 Perspective Therapeutics Shares at $3.12 Each - Kalkine Media
Perspective Therapeutics (CATX) backer trims stake but keeps 11.5M shares - Stock Titan
10% owner of Perspective Therapeutics (NYSE: CATX) sells 113,914 shares over two days - Stock Titan
Perspective Therapeutics (CATX) backer Lantheus now owns 10% after share sales - Stock Titan
Perspective Therapeutics Inc (CATX) Insider Sell: 10% Owner Holdings, Lantheus Disposes of 35,769 Shares - GuruFocus
Perspective Therapeutics (CATX) holder sells 35K shares, still owns 11.6M - Stock Titan
Perspective Therapeutics Inc (CATX) Insider Sell: 10% Owner Holdings, Lantheus Disposes of 78,145 Shares - GuruFocus
Lantheus Holdings sells $245,609 in Perspective Therapeutics stock By Investing.com - Investing.com Nigeria
Lantheus Holdings sells $245,609 in Perspective Therapeutics stock - Investing.com
CATX Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.22 Beats EstimatesShort-Term Outlook - dars.gov.et
Perspective Therapeutics: 'Strong Buy' On Bamzireotide Navoxetan Reinforced Data And Phase 3 Plans - Seeking Alpha
Perspective Therapeutics (CATX) Slides 3.19% as $3.03 Support Comes into FocusMomentum Surge Alerts - vinanet.vn
Perspective (CATX) Quarterly Results: Reported EPS Tops Expectations at the Close; Post-Earnings: The Market Price Declines 3.03% for the Current SessionProfit Inflection Point - vinanet.vn
Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Eastern Progress
BMO Capital Markets Upgrades Perspective Therapeutics (NYSEAMERICAN:CATX) to "Strong-Buy" - MarketBeat
Perspective (CATX) Range: Posts a 8.41% Gain to $3.48 for the Current Session; Chart View - vinanet.vn
PERSPECTIVE THERAPEUTICS INC : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $11 - Bitget
Perspective Therapeutics Market Sentiment - Benzinga France
CATX Initiated by BMO Capital -- Rating Set to Outperform - GuruFocus
Perspective Therapeutics Price Target Announced at $11.00/Share by BMO Capital - Moomoo
BMO initiates Perspective Therapeutics stock at Outperform, $11 target By Investing.com - Investing.com South Africa
BMO initiates Perspective Therapeutics stock at Outperform, $11 target - Investing.com
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
0.97%
Cap:
|
Volume (24h):